SGLT抑制剂和生理介质的作用机制:MOSAIC协作元分析的系统审查和协议
Luxcia Kugathasan1,2, Massimo Nardone1, Marcel Muskiet1
1University Health Network, Toronto, Ontario, Canada.
BMJ open
|February 26, 2026
概括
-葡萄糖共运输体 (SGLT) 抑制剂有益于心血管和脏健康,但机制尚不清楚. 这一元分析汇总了24项研究的数据,以澄清SGLT抑制.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖携带载体 (SGLT) 抑制剂具有显著的心血管和脏益处.
- 这些好处背后的精确生理机制仍然不完全理解.
- 现有的机械学研究在设计,功率和一致性方面存在局限性.
研究的目的:
- 进行机理学研究中的个人参与者数据的系统审查和元分析.
- 为了确定与SGLT抑制相关的一致生理模式.
- 提高对SGLT抑制剂治疗效果的理解.
主要方法:
- 使用贝叶斯框架进行系统审查和个人参与者数据元分析 (IPD MA).
- 包括通过全面的数据库搜索确定的24项机制研究 (n=1296).
- 提取关键变量,包括测量膜过率 (mGFR),血液动力学和生物化学标记.
主要成果:
- 该元分析将汇总来自24项研究的数据,其中包括1296名参与者.
- 分析的重点是测量膜过率 (mGFR) 的初级结果.
- 探索脏血液动力学,管状处理和心血管参数.
结论:
- 这项研究是对SGLT抑制机制的个人参与者数据的首次元分析.
- 研究结果将提供关于生理效应的强有力的,可概括的结论.
- 更好的理解将为临床应用和未来的研究提供信息.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
77
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
Glucose Transporters
27.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
672
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
672
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786

